POM-V Prescription Required Companion Animal

Prevomax

Active ingredient: Maropitant

Form

Injection

Species

Cats Dogs

Manufacturer

Dechra Regulatory BV

VMD MA No.

EU/2/17/211/001-004

What it's used for

Cats - by motion sickness. - AN: 01464/2024Page 2 of 8

Full indications, dosage and side effects ↓

View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Maropitant

1

Ask your vet for a written prescription

They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
2

Fill it at a registered online retailer

The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Your prescription rights → VMD register of retailers →

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Prevomax — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 27 Mar 2026.

Cats
-
by motion sickness.
-
AN: 01464/2024Page 2 of 8

The veterinary medicinal product should be injected subcutaneously or intravenously,
once daily, at a dose of 1 mg/kg bodyweight (1 ml/10 kg bodyweight) for up to 5
consecutive days. Intravenous administration of the veterinary medicinal product
should be given as a single bolus without mixing the veterinary medicinal product
with any other fluids.
To prevent vomiting, the veterinary medicinal product should be administered more
than 1 hour in advance. The effect duration is approximately 24 h and therefore
treatment can be given the night before administration of an agent that may cause
emesis e.g. chemotherapy.
As the pharmacokinetic variation is large and maropitant accumulates in the body
after once daily repeated administration, lower doses than recommended might be
sufficient in some individuals and when repeating the dose.
For administration by subcutaneous injection, see also “Special precautions for safe
use in the target species” (section 3.5).
The cap may be safely punctured up to 40 times. It is recommended that a draw-off
needle be used to reduce the number of times the septum is punctured.

None.

Dogs, cats:
Very common
(>1 animal / 10 animals
treated):
Injection site pain.
1,2
Very rare
(<1 animal / 10,000 animals
treated, including isolated
reports):
Anaphylactic-type reaction (allergic oedema,
urticaria, erythema, collapse, dyspnoea, pale
mucous membrane).
Lethargy.
Neurological disorders (ataxia, convulsion/seizure
or muscle tremor).
When injected subcutaneously to cat: moderate to severe response to injection (in
approximately one third of cats).
When injected subcutaneously to dog.
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to
either the marketing authorisation holder or its local representative or the national
competent authority via the national reporting system. See the package leaflet for
respective contact details.
AN: 01464/2024Page 4 of 8

Vomiting can be associated with serious, severely debilitating conditions including
gastrointestinal obstructions; therefore, appropriate diagnostic evaluations should be
employed.
Good veterinary practice indicates that antiemetics should be used in conjunction
with other veterinary and supportive measures such as dietary control and fluid
replacement therapy while addressing the underlying causes of the vomiting.
The use of the veterinary medicinal product against vomiting due to motion sickness
is not recommended.
Dogs:
Although maropitant has been demonstrated to be effective in both the treatment and
prevention of emesis induced by chemotherapy, it was found more efficacious if used
preventively. Therefore, it is recommended to administer the antiemetic prior to
administration of the chemotherapeutic agent.
Cats:
The efficacy of maropitant in reduction of nausea was demonstrated in studies using
a model (xylazine induced nausea).

Special precautions for safe use in the target species:
The safety of the veterinary medicinal product has not been established in dogs less
than 8 weeks of age, or in cats less than 16 weeks of age, and in pregnant or
lactating dogs and cats. Use only according to the benefit-risk assessment by the
responsible veterinarian.
Maropitant is metabolised in the liver and therefore should be used with caution in
patients with hepatic disease. As maropitant is accumulated in the body during a 14-
day treatment period due to metabolic saturation, careful monitoring of liver function
and any adverse events should be implemented during long term treatment.
The veterinary medicinal product should be used with caution in animals suffering
from or with predisposition for cardiac diseases as maropitant has affinity to Ca- and
K-ion channels. Increases of approximately 10% in the QT interval of the ECG were
observed in a study on healthy beagle dogs administered 8 mg/kg orally; however,
such an increase is unlikely to be of clinical significance.
Due to the frequent occurrence of transient pain during subcutaneous injection,
appropriate animal restraining measures may have to be applied. Injecting the
veterinary medicinal product at refrigerated temperature may reduce pain at injection.
AN: 01464/2024Page 3 of 8
Special precautions to be taken by the person administering the veterinary medicinal
product to animals:
Maropitant is a neurokinin-1 (NK1) receptor antagonist that acts in the central nervous
system. The veterinary medicinal product may therefore cause nausea, dizziness and
drowsiness in case of accidental self-injection. If accidental self-injection occurs, seek
medical advice immediately and show the package leaflet or the label to the physician.
Due to the content of benzyl alcohol the veterinary medicinal product may cause mild
local irritation. Skin contact should therefore be avoided. In case of accidental
exposure, wash affected skin area with plenty of water.
The veterinary medicinal product may cause skin sensitisation. People with known
hypersensitivity to maropitant or to any of the excipients should administer the
veterinary medicinal product with caution. If you develop symptoms such as a skin rash
after accidental exposure, seek medical advice and show the physician this warning.
The veterinary medicinal product may cause eye irritation. Eye contact should be
avoided. In case of accidental eye exposure, flush the eyes with plenty of water and
seek medical attention.
Wash hands after use.
Special precautions for the protection of the environment:
Not applicable.

The veterinary medicinal product should not be used concomitantly with Ca-channel
antagonists as maropitant has affinity to Ca-channels.
Maropitant is highly bound to plasma proteins and may compete with other highly
bound medicines.

This veterinary medicinal product does not require any special storage conditions.

Not applicable.

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.